Summary
Dr. Reddy's has entered India's biosimilar immuno-oncology market with the launch of Nivorz, targeting a sector estimated at ₹3,900 crore in 2025, primarily driven by checkpoint inhibitors.
Dr. Reddy's Enters India's Biosimilar Immuno-Oncology Market with Nivorz Launch
HyperFast News
Related news
Dr. Reddy's Aurigene Signs Long-Term Manufacturing Pact with Global Pharma Major
19 Sept 2026, 10:35 am · News
Dr. Reddy's, Novartis India Terminate Agreement; Novartis Reacquires Product Rights
19 Sept 2026, 10:35 am · News
Dr. Reddy's Q1 Net Plunges 69% to ₹435.6 Cr on Lower Revenue
19 Sept 2026, 10:35 am · News
